Vedolizumab for the Treatment of Chronic Pouchitis

2023106 citationsJournal Articlegreen Open Access

Authors

Simon Travis · Western University

Mark S. Silverberg · Western University

Silvio Danese · Western University

Paolo Gionchetti · Western University

Mark Löwenberg · Western University

Vipul Jairath · Western University

Brian G. Feagan ·

Abstract

Treatment with vedolizumab was more effective than placebo in inducing remission in patients who had chronic pouchitis after undergoing IPAA for ulcerative colitis. (Funded by Takeda; EARNEST ClinicalTrials.gov number, NCT02790138; EudraCT number, 2015-003472-78.).

Topics & Keywords

Autoimmune and Inflammatory Disorders IgG4-Related and Inflammatory Diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 13, pp. 1191-1200

DOI: 10.1056/nejmoa2208450

Field-Weighted Citation Impact: 22.64